Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dasatinib
Drug ID BADD_D00589
Description Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
Indications and Usage For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Marketing Status Prescription
ATC Code L01EA02
DrugBank ID DB01254
KEGG ID D03658
MeSH ID D000069439
PubChem ID 3062316
TTD Drug ID D0E6XR
NDC Product Code 63285-862; 63285-867; 0003-0855; 63285-863; 63285-866; 63285-865; 68554-0070; 54893-0015; 54893-0047; 0003-0857; 0003-0852; 0003-0527; 0003-0528; 76302-014; 50193-0524; 46708-891; 14778-1313; 62207-973; 63285-864; 0003-0524; 59651-468; 53104-7725
Synonyms Dasatinib | N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | Sprycel | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | BMS 354825 | 354825, BMS | BMS354825 | BMS-354825
Chemical Information
Molecular Formula C22H26ClN7O2S
CAS Registry Number 302962-49-8
SMILES CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Splenomegaly01.09.02.0010.003197%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.000533%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.0050.005861%
Stress19.06.02.004--Not Available
Subarachnoid haemorrhage17.08.01.010; 12.01.10.011; 24.07.04.004--Not Available
Subdural haematoma24.07.04.005; 17.08.05.002; 12.01.10.003--Not Available
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Sunburn23.03.09.007; 12.05.02.0010.001598%Not Available
Swelling08.01.03.0150.010124%Not Available
Swelling face23.04.01.018; 10.01.05.0180.004263%Not Available
Swollen tongue10.01.05.015; 07.14.02.003; 23.04.01.014--Not Available
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Systemic lupus erythematosus rash23.03.13.007; 15.06.02.005; 10.04.03.005--Not Available
T-cell lymphoma11.05.17.006; 16.17.02.001; 01.11.02.0010.000139%Not Available
Tachycardia02.03.02.007--Not Available
Tenderness08.01.08.005--Not Available
Tendonitis15.07.01.003; 12.01.07.007--Not Available
Tension19.06.02.005--Not Available
Thirst08.01.09.021; 14.03.02.0070.001332%Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
Thrombocytopenia01.08.01.0020.019448%Not Available
Thrombocytosis01.08.02.0010.000799%Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.0060.000799%Not Available
Thrombotic thrombocytopenic purpura01.08.01.005; 24.07.06.014; 23.06.01.0110.000533%
Thyroid function test abnormal13.10.06.0010.000533%Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 30 Pages